Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 706

1.

Adult hepatocytes direct liver organogenesis through non-parenchymal cell recruitment in the kidney.

Utoh R, Komori J, Kuge H, Tatsumi K, Yamada M, Hirohashi S, Tsutsumi M, Amanuma T, Yoshioka A, Nakajima Y, Wake K, Okano T, Lagasse E, Ohashi K.

J Hepatol. 2017 Dec 26. pii: S0168-8278(17)32531-X. doi: 10.1016/j.jhep.2017.12.016. [Epub ahead of print]

PMID:
29288124
2.

Induction, cloning and functional expression of a sesquiterpene biosynthetic enzyme, δ-guaiene synthase, of Aquilaria microcarpa cell cultures.

Lee JB, Hirohashi S, Yamamura Y, Taura F, Kurosaki F.

Nat Prod Commun. 2014 Sep;9(9):1231-5.

PMID:
25918780
3.

Genome-wide DNA methylation profiles in renal tumors of various histological subtypes and non-tumorous renal tissues.

Arai E, Wakai-Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y.

Pathobiology. 2011;78(1):1-9. doi: 10.1159/000322072. Epub 2011 Apr 5.

4.

Clinicopathological significance of nuclear factor-κB activation in hepatocellular carcinoma.

Yokoo H, Yasuda J, Nakanishi K, Chuma M, Kamiyama T, Todo S, Hirohashi S, Sakamoto M.

Hepatol Res. 2011 Mar;41(3):240-9. doi: 10.1111/j.1872-034X.2010.00758.x. Epub 2011 Jan 27.

PMID:
21272165
5.

Significance of dysadherin and E-cadherin expression in differentiated-type gastric carcinoma with submucosal invasion.

Maehata Y, Hirahashi M, Aishima S, Kishimoto J, Hirohashi S, Yao T, Takashima H, Tsuneyoshi M, Oda Y.

Hum Pathol. 2011 Apr;42(4):558-67. doi: 10.1016/j.humpath.2010.08.016. Epub 2011 Jan 15.

PMID:
21239043
6.

Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer.

Matsubara J, Honda K, Ono M, Tanaka Y, Kobayashi M, Jung G, Yanagisawa K, Sakuma T, Nakamori S, Sata N, Nagai H, Ioka T, Okusaka T, Kosuge T, Tsuchida A, Shimahara M, Yasunami Y, Chiba T, Hirohashi S, Yamada T.

Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):160-71. doi: 10.1158/1055-9965.EPI-10-0397. Epub 2010 Dec 8.

7.

Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics.

Kikuta K, Tochigi N, Saito S, Shimoda T, Morioka H, Toyama Y, Hosono A, Suehara Y, Beppu Y, Kawai A, Hirohashi S, Kondo T.

Proteomics Clin Appl. 2010 May;4(5):560-7. doi: 10.1002/prca.200900172. Epub 2010 Feb 26.

PMID:
21137073
8.

A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer.

Saeki N, Saito A, Choi IJ, Matsuo K, Ohnami S, Totsuka H, Chiku S, Kuchiba A, Lee YS, Yoon KA, Kook MC, Park SR, Kim YW, Tanaka H, Tajima K, Hirose H, Tanioka F, Matsuno Y, Sugimura H, Kato S, Nakamura T, Nishina T, Yasui W, Aoyagi K, Sasaki H, Yanagihara K, Katai H, Shimoda T, Yoshida T, Nakamura Y, Hirohashi S, Sakamoto H.

Gastroenterology. 2011 Mar;140(3):892-902. doi: 10.1053/j.gastro.2010.10.058. Epub 2010 Nov 8.

PMID:
21070779
9.

Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway.

Shibata T, Saito S, Kokubu A, Suzuki T, Yamamoto M, Hirohashi S.

Cancer Res. 2010 Nov 15;70(22):9095-105. doi: 10.1158/0008-5472.CAN-10-0384. Epub 2010 Nov 9.

10.

CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis.

Hiraoka N, Yamazaki-Itoh R, Ino Y, Mizuguchi Y, Yamada T, Hirohashi S, Kanai Y.

Gastroenterology. 2011 Jan;140(1):310-21. doi: 10.1053/j.gastro.2010.10.009. Epub 2010 Oct 16.

PMID:
20955708
11.

Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites.

Mitselou A, Batistatou A, Nakanishi Y, Hirohashi S, Vougiouklakis T, Charalabopoulos K.

Histol Histopathol. 2010 Oct;25(10):1257-67. doi: 10.14670/HH-25.1257.

PMID:
20712010
12.

Traf2- and Nck-interacting kinase is essential for canonical Wnt signaling in Xenopus axis formation.

Satow R, Shitashige M, Jigami T, Honda K, Ono M, Hirohashi S, Yamada T.

J Biol Chem. 2010 Aug 20;285(34):26289-94. doi: 10.1074/jbc.M109.090597. Epub 2010 Jun 21.

13.

Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma.

Akishima-Fukasawa Y, Ino Y, Nakanishi Y, Miura A, Moriya Y, Kondo T, Kanai Y, Hirohashi S.

Am J Clin Pathol. 2010 Jul;134(1):71-9. doi: 10.1309/AJCPRJP39MIDSGBH.

PMID:
20551269
14.

DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung.

Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, Tsuta K, Asamura H, Matsuno Y, Kondo T, Imoto I, Inazawa J, Hirohashi S.

Oncogene. 2010 Aug 19;29(33):4671-81. doi: 10.1038/onc.2010.217. Epub 2010 Jun 14.

PMID:
20543864
15.

Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth.

Shitashige M, Satow R, Jigami T, Aoki K, Honda K, Shibata T, Ono M, Hirohashi S, Yamada T.

Cancer Res. 2010 Jun 15;70(12):5024-33. doi: 10.1158/0008-5472.CAN-10-0306. Epub 2010 Jun 8.

16.

Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.

Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, Honda K, Kosuge T, Ochiya T, Hirohashi S, Yamada T.

Clin Cancer Res. 2010 May 1;16(9):2518-28. doi: 10.1158/1078-0432.CCR-09-2214. Epub 2010 Apr 13.

17.

Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma.

Kobayashi E, Masuda M, Nakayama R, Ichikawa H, Satow R, Shitashige M, Honda K, Yamaguchi U, Shoji A, Tochigi N, Morioka H, Toyama Y, Hirohashi S, Kawai A, Yamada T.

Mol Cancer Ther. 2010 Mar;9(3):535-44. doi: 10.1158/1535-7163.MCT-09-0774. Epub 2010 Feb 16.

18.

Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.

Ichikawa T, Saito K, Yoshioka N, Tanimoto A, Gokan T, Takehara Y, Kamura T, Gabata T, Murakami T, Ito K, Hirohashi S, Nishie A, Saito Y, Onaya H, Kuwatsuru R, Morimoto A, Ueda K, Kurauchi M, Breuer J.

Invest Radiol. 2010 Mar;45(3):133-41. doi: 10.1097/RLI.0b013e3181caea5b.

PMID:
20098330
19.

Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment.

Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Hirohashi S, Kanai Y, Shibata T.

Cancer Sci. 2010 Apr;101(4):882-8. doi: 10.1111/j.1349-7006.2009.01462.x. Epub 2009 Dec 8.

20.

Survival prediction for pancreatic cancer patients receiving gemcitabine treatment.

Matsubara J, Ono M, Honda K, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Shoji A, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T.

Mol Cell Proteomics. 2010 Apr;9(4):695-704. doi: 10.1074/mcp.M900234-MCP200. Epub 2010 Jan 8.

21.

Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer.

Kubo T, Kuroda Y, Kokubu A, Hosoda F, Arai Y, Hiraoka N, Hirohashi S, Shibata T.

Pancreas. 2009 Oct;38(7):e200-6. doi: 10.1097/MPA.0b013e3181b8feb0.

PMID:
19893451
22.

Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities.

Kikuta K, Gotoh M, Kanda T, Tochigi N, Shimoda T, Hasegawa T, Katai H, Shimada Y, Suehara Y, Kawai A, Hirohashi S, Kondo T.

Jpn J Clin Oncol. 2010 Jan;40(1):60-72. doi: 10.1093/jjco/hyp125. Epub 2009 Oct 7.

PMID:
19815537
23.

Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage.

Nishiyama N, Arai E, Chihara Y, Fujimoto H, Hosoda F, Shibata T, Kondo T, Tsukamoto T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y.

Cancer Sci. 2010 Jan;101(1):231-40. doi: 10.1111/j.1349-7006.2009.01330.x. Epub 2009 Aug 27.

24.

Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer.

Kubo T, Kuroda Y, Shimizu H, Kokubu A, Okada N, Hosoda F, Arai Y, Nakamura Y, Taniguchi H, Yanagihara K, Imoto I, Inazawa J, Hirohashi S, Shibata T.

Carcinogenesis. 2009 Nov;30(11):1857-64. doi: 10.1093/carcin/bgp206. Epub 2009 Sep 4.

PMID:
19734198
25.

Functional genome screen for therapeutic targets of osteosarcoma.

Yamaguchi U, Honda K, Satow R, Kobayashi E, Nakayama R, Ichikawa H, Shoji A, Shitashige M, Masuda M, Kawai A, Chuman H, Iwamoto Y, Hirohashi S, Yamada T.

Cancer Sci. 2009 Dec;100(12):2268-74. doi: 10.1111/j.1349-7006.2009.01310.x. Epub 2009 Aug 10.

26.

Application of 2D-DIGE in cancer proteomics toward personalized medicine.

Kondo T, Hirohashi S.

Methods Mol Biol. 2009;577:135-54. doi: 10.1007/978-1-60761-232-2_11.

PMID:
19718514
27.

Prolyl 4-hydroxylation of alpha-fibrinogen: a novel protein modification revealed by plasma proteomics.

Ono M, Matsubara J, Honda K, Sakuma T, Hashiguchi T, Nose H, Nakamori S, Okusaka T, Kosuge T, Sata N, Nagai H, Ioka T, Tanaka S, Tsuchida A, Aoki T, Shimahara M, Yasunami Y, Itoi T, Moriyasu F, Negishi A, Kuwabara H, Shoji A, Hirohashi S, Yamada T.

J Biol Chem. 2009 Oct 16;284(42):29041-9. doi: 10.1074/jbc.M109.041749. Epub 2009 Aug 20.

28.

Tyrosine-phosphorylation of the 12th armadillo-repeat of beta-catenin is associated with cadherin dysfunction in human cancer.

Shomori K, Ochiai A, Akimoto S, Ino Y, Shudo K, Ito H, Hirohashi S.

Int J Oncol. 2009 Sep;35(3):517-24.

PMID:
19639172
29.

Prognostic significance of CXCL12 expression in patients with colorectal carcinoma.

Akishima-Fukasawa Y, Nakanishi Y, Ino Y, Moriya Y, Kanai Y, Hirohashi S.

Am J Clin Pathol. 2009 Aug;132(2):202-10; quiz 307. doi: 10.1309/AJCPK35VZJEWCUTL.

PMID:
19605814
30.

Krüppel-like factor 12 plays a significant role in poorly differentiated gastric cancer progression.

Nakamura Y, Migita T, Hosoda F, Okada N, Gotoh M, Arai Y, Fukushima M, Ohki M, Miyata S, Takeuchi K, Imoto I, Katai H, Yamaguchi T, Inazawa J, Hirohashi S, Ishikawa Y, Shibata T.

Int J Cancer. 2009 Oct 15;125(8):1859-67. doi: 10.1002/ijc.24538.

31.

Genome-wide DNA methylation profiles in liver tissue at the precancerous stage and in hepatocellular carcinoma.

Arai E, Ushijima S, Gotoh M, Ojima H, Kosuge T, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y.

Int J Cancer. 2009 Dec 15;125(12):2854-62. doi: 10.1002/ijc.24708.

32.

Antibody-based proteomics for esophageal cancer: Identification of proteins in the nuclear factor-kappaB pathway and mitotic checkpoint.

Uemura N, Nakanishi Y, Kato H, Nagino M, Hirohashi S, Kondo T.

Cancer Sci. 2009 Sep;100(9):1612-22. doi: 10.1111/j.1349-7006.2009.01230.x. Epub 2009 May 28.

33.

Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma.

Yamanashi T, Nakanishi Y, Fujii G, Akishima-Fukasawa Y, Moriya Y, Kanai Y, Watanabe M, Hirohashi S.

Oncology. 2009;77(1):53-62. doi: 10.1159/000226112. Epub 2009 Jun 25.

PMID:
19556810
34.

Quantitative proteomics using formalin-fixed paraffin-embedded tissues of oral squamous cell carcinoma.

Negishi A, Masuda M, Ono M, Honda K, Shitashige M, Satow R, Sakuma T, Kuwabara H, Nakanishi Y, Kanai Y, Omura K, Hirohashi S, Yamada T.

Cancer Sci. 2009 Sep;100(9):1605-11. doi: 10.1111/j.1349-7006.2009.01227.x. Epub 2009 May 18.

35.

Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.

Shibata T, Kokubu A, Tsuta K, Hirohashi S.

Cancer Lett. 2009 Oct 8;283(2):203-11. doi: 10.1016/j.canlet.2009.03.038. Epub 2009 Apr 25.

PMID:
19394761
36.

Nucleophosmin as a candidate prognostic biomarker of Ewing's sarcoma revealed by proteomics.

Kikuta K, Tochigi N, Shimoda T, Yabe H, Morioka H, Toyama Y, Hosono A, Beppu Y, Kawai A, Hirohashi S, Kondo T.

Clin Cancer Res. 2009 Apr 15;15(8):2885-94. doi: 10.1158/1078-0432.CCR-08-1913. Epub 2009 Apr 7.

37.

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.

Yoshikawa D, Ojima H, Kokubu A, Ochiya T, Kasai S, Hirohashi S, Shibata T.

Br J Cancer. 2009 Apr 21;100(8):1257-66. doi: 10.1038/sj.bjc.6604988. Epub 2009 Mar 24.

38.

Identification of a predictive biomarker for hematologic toxicities of gemcitabine.

Matsubara J, Ono M, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Honda K, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T.

J Clin Oncol. 2009 May 1;27(13):2261-8. doi: 10.1200/JCO.2008.19.9745. Epub 2009 Mar 16.

PMID:
19289617
39.

Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging.

Marugami N, Tanaka T, Kitano S, Hirohashi S, Nishiofuku H, Takahashi A, Sakaguchi H, Matsuoka M, Otsuji T, Takahama J, Higashiura W, Kichikawa K.

Cardiovasc Intervent Radiol. 2009 Jul;32(4):638-46. doi: 10.1007/s00270-009-9532-8. Epub 2009 Feb 24.

PMID:
19238482
40.

Adenylate cyclase-associated protein 1 overexpressed in pancreatic cancers is involved in cancer cell motility.

Yamazaki K, Takamura M, Masugi Y, Mori T, Du W, Hibi T, Hiraoka N, Ohta T, Ohki M, Hirohashi S, Sakamoto M.

Lab Invest. 2009 Apr;89(4):425-32. doi: 10.1038/labinvest.2009.5. Epub 2009 Feb 2.

41.

Large-scale quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry.

Negishi A, Ono M, Handa Y, Kato H, Yamashita K, Honda K, Shitashige M, Satow R, Sakuma T, Kuwabara H, Omura K, Hirohashi S, Yamada T.

Cancer Sci. 2009 Mar;100(3):514-9. doi: 10.1111/j.1349-7006.2008.01055.x. Epub 2008 Dec 19.

42.

Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics.

Uemura N, Nakanishi Y, Kato H, Saito S, Nagino M, Hirohashi S, Kondo T.

Int J Cancer. 2009 May 1;124(9):2106-15. doi: 10.1002/ijc.24194.

43.

Safety of ferucarbotran in MR imaging of the liver: a pre- and postexamination questionnaire-based multicenter investigation.

Onishi H, Murakami T, Kim T, Hori M, Hirohashi S, Matsuki M, Narumi Y, Imai Y, Sakurai K, Nakamura H.

J Magn Reson Imaging. 2009 Jan;29(1):106-11. doi: 10.1002/jmri.21608.

PMID:
19097079
44.

Molecular background of alpha-fetoprotein in liver cancer cells as revealed by global RNA expression analysis.

Saito S, Ojima H, Ichikawa H, Hirohashi S, Kondo T.

Cancer Sci. 2008 Dec;99(12):2402-9. doi: 10.1111/j.1349-7006.2008.00973.x. Epub 2008 Nov 24.

45.

Intraductal carcinoma component as a favorable prognostic factor in biliary tract carcinoma.

Ojima H, Kanai Y, Iwasaki M, Hiraoka N, Shimada K, Sano T, Sakamoto Y, Esaki M, Kosuge T, Sakamoto M, Hirohashi S.

Cancer Sci. 2009 Jan;100(1):62-70. doi: 10.1111/j.1349-7006.2008.01009.x. Epub 2008 Nov 25. Erratum in: Cancer Sci. 2009 Jun;100(6):1144.

46.

Genome-wide DNA methylation profiles in both precancerous conditions and clear cell renal cell carcinomas are correlated with malignant potential and patient outcome.

Arai E, Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y.

Carcinogenesis. 2009 Feb;30(2):214-21. doi: 10.1093/carcin/bgn268. Epub 2008 Nov 26.

47.

Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma.

Orimo T, Ojima H, Hiraoka N, Saito S, Kosuge T, Kakisaka T, Yokoo H, Nakanishi K, Kamiyama T, Todo S, Hirohashi S, Kondo T.

Hepatology. 2008 Dec;48(6):1851-63. doi: 10.1002/hep.22552.

PMID:
18937283
48.

Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome.

Arai E, Ushijima S, Tsuda H, Fujimoto H, Hosoda F, Shibata T, Kondo T, Imoto I, Inazawa J, Hirohashi S, Kanai Y.

Clin Cancer Res. 2008 Sep 1;14(17):5531-9. doi: 10.1158/1078-0432.CCR-08-0443.

49.

Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas.

Kikuchi S, Honda K, Tsuda H, Hiraoka N, Imoto I, Kosuge T, Umaki T, Onozato K, Shitashige M, Yamaguchi U, Ono M, Tsuchida A, Aoki T, Inazawa J, Hirohashi S, Yamada T.

Clin Cancer Res. 2008 Sep 1;14(17):5348-56. doi: 10.1158/1078-0432.CCR-08-0075.

50.

Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.

Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, Asamura H, Yamamoto M, Hirohashi S.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13568-73. doi: 10.1073/pnas.0806268105. Epub 2008 Aug 29. Erratum in: Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10393.

Supplemental Content

Loading ...
Support Center